Rivoglitazone

Rivoglitazone

File:Rivoglitazone.svg
Identifiers
IUPAC name 5-{4-[(6-methoxy-1-methyl-1H-benzimidazol-2-yl) methoxy]benzyl}-1,3-thiazolidine-2,4-dione
CAS Number	185428-18-6
PubChem CID	3055168
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C20H19N3O4S
Molar mass	397.448 g/mol
3D model (JSmol)	Interactive image
SMILES CN1C2=C(C=CC(=C2)OC)N=C1COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Rivoglitazone (INN) is a thiazolidinedione undergoing research for use in the treatment of type 2 diabetes.

It is being developed by Daiichi Sankyo Co.